Oral etoposide for refractory and relapsed neuroblastoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Bone Marrow Neoplasms
  • Etoposide
  • Neoplasm Recurrence, Local
  • Neuroblastoma

abstract

  • Given the absence of toxicity to major organs, the minimal myelosuppression or immunosuppression, and the antineoplastic activity in patients with low tumor burdens after high-dose chemotherapy, limited use of low-dose oral etoposide should be considered for inclusion in postinduction consolidative treatment programs aimed at eradicating minimal residual disease.

publication date

  • October 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10506622

Additional Document Info

start page

  • 3221

end page

  • 5

volume

  • 17

number

  • 10